Molecular imaging modalities are used for in vivo assessment of pathology, and nuclear medicine tracers can facilitate early diagnosis and evaluation of therapy response. Furthermore, molecular radionuclide therapy –using radionuclides with therapeutic instead of diagnostic properties– also allows for targeted treatment. The group focuses on investigations of biodistribution, dosimetry and treatment planning for existing and novel radionuclide therapies, in order to improve the treatment regimens or introduce new radiopharmaceuticals in the clinic. Furthermore, the research group is performing quantitative PET and SPECT imaging studies, pharmacokinetic modelling and advanced image analyses in various clinical trials. 

• Therapeutic nuclear medicine: Theranostic radiopharmaceuticals for metastatic cancer -focusing on targeted alpha therapy (Co-lead, South-Eastern Norway Regional Health Authority Grant), SIMPLERAD (Co-lead WP4, funded by the European Union), Biodistribution and dosimetry in a phase 1 trial of 224-Ra-CaCO₃ particles (funded by sponsor), Dose-effects for a novel 177-Lu based treatment of non-Hodgkin lymphoma (South-Eastern Norway Regional Health Authority Research Grant), Simulation tools and quantitative 90-Y PET/CT for Selective Internal Radiation Therapy (South-Eastern Norway Regional Health Authority Innovation Grant), Dosimetry-based treatment planning of 131-I therapy.
• Other studies: Quantitative PET parameters as predictors for patient outcome (part of different lymphoma trials), radiomics investigations, novel PET tracers for multiple myeloma assessments, and various technical projects related to image reconstruction and analyses.

Contact information
Group Leader Caroline Stokke, PhD, Assoc. Prof., Department of Physics and Computational Radiology, carsto@ous-hf.no, (0047) 98685214

Contact information
Group Leader Caroline Stokke, PhD, Assoc. Prof., Department of Physics and Computational Radiology, carsto@ous-hf.no, (0047) 98685214